Trials posted here are for informational purposes only. NeuroEndocrine Cancer Australia does not endorse any particular research study and is not responsible for the accuracy of the information provided by the investigator or the accuracy of the information provided by the searchable databases.

AUS-NET - Neuroendocrine Tumours

“Our trial is a world first and the knowledge generated will inform health care policy to completely transform the way people with neuroendocrine cancer, and other rare cancers in the future, are cared for.”

– David Chan

Neuroendocrine tumours (NETs) are rare cancers that affect fewer than 1 in 5,000 Australians, but those who live with them suffer from a lot of distressing symptoms and treatment side effects. Rare conditions such as NETs do not receive medical advancements at the same rate as common ones. Under our current health system, the needs of cancer survivors are not always met. Our health system, particularly acute care, is under extreme strain which impacts the care available to patients. 

Goal

To improve patient quality of life and develop a cost-effective system that can be implemented across other rare cancers in the future.

Rethinking the health care system to represent a share-care model, including support from General Practitioners and local health workers to address unmet needs of people with Neuroendocrine Tumours and relieve pressure from specialist care.

Aims

Implement a new share-care model for the care of people with neuroendocrine tumours focusing on including local health professionals, including GPs, in the follow-up structure, moving patients away from hospitals and acute care.

Improve the model of care for patients with neuroendocrine tumours, and other rare cancers in the future.

Chief Investigator: Professor Raymond Chan

Collaborators
  • University of Melbourne, Melbourne, Victoria
  • Peter MacCallum Cancer Centre, Melbourne, Victoria
  • Queensland University of Technology, Brisbane, Queensland
  • The Queen Elizabeth Hospital, Adelaide, South Australia
  • Royal Brisbane and Women’s Hospital, Brisbane, Queensland
  • Royal North Shore Hospital, Sydney, New South Wales
  • Fiona Stanley Hospital, Perth, Western Australia

Project Partners

  • Neuroendocrine Cancer Australia (NECA)
  • Primary Care Collaborative Cancer Clinical Trials Group (PC4)
  • Royal Australasian College for General Practitioners (RACGP)
  • Australian Healthcare and Hospitals Association (AHHA)
  • Cancer Nurses Society of Australia (CNSA)

Study Sites

  • Peter MacCallum Cancer Centre, Melbourne, Victoria (Principal  Investigator – Prof Michael Michael)
  • The Queen Elizabeth Hospital, Adelaide, South Australia (Principal Investigator – A/Prof Gaby Cehic)
  • Royal Brisbane and Women’s Hospital, Brisbane, Queensland (Principal Investigator – A/ Prof David Wyld)
  • Royal North Shore Hospital, Sydney, New South Wales (Principal Investigator – Dr David Chan
  • Fiona Stanley Hospital, Perth, Western Australia (Principal Investigator – Dr David Ransom)

For more information please contact your NET centre and the Principal Investigator, alternately contact NECA NET Nurse Dana Hart dana@neuroendocrine.org.au

Commenced: 2022 

Completion due: 2027 

Anxiety in oncology, multiple sclerosis and eating disorder populations: A comparison with the general community

Researchers at The University of Melbourne are interested in psychological factors that contribute to the development and maintenance of anxiety in those with a current or previous diagnosis of Cancer.
 
This online study will explore relationships between psychological qualities like personality traits, attitudes, emotions and beliefs and will take approx. 30 minutes to complete. Please note this study will ask questions about death or illness anxiety, and beliefs around weight, life, religion and meaning.
 
Participation involves filling out a short online questionnaire at three time points, on your phone or your computer. You can choose to opt out at any time.
 
Participants will have a chance to win 1 of 11 AUD$100 e-gift cards for completing both Time 1 and 2 surveys and another 1 of 11 AUD$100 e-gift cards after completing Time 3.
 
Participation is voluntary and all data will remain confidential.
 
HREC Project ID Number: 25728
 
To find out more and to participate click here. 
 

A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

Phase: Phase 3
Sponsor: Camurus AB

Fiona Stanley Hospital (Oncology)
11 Robin Warren Dr, Murdoch WA 6150, Australia
 
Primary Contact : Caroline Stone, caroline.stone@health.wa.gov.au , (08) 6152 6530
Secondary Contact : Edwin Tan, Edwin.tan@health.wa.gov.au , 61861526720
 
Read more here.

 

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Read more here.

compose header

Study to look at well-differentiated advanced Grade 2 and Grade 3 somatostatin receptor positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 & G3 GEP-NETs)

Investigational treatment
Targeted Radionuclide Therapy with n.c.a. Lutetium-177-Edotreotide, consisting of the highly pure medical radioisotope, no-carrier-added (n.c.a.) Lutetium-177, used to destroy tumor cells, and the molecule Edotreotide, which targets neuroendocrine tumor-specific receptors and delivers the medical radioisotope to the tumor site.

What is Targeted Radionuclide Therapy?
In contrast to external radiotherapy, where radiation is applied from outside the body, Targeted Radionuclide Therapy isdefined by the infusion of a radiopharmaceutical into the body which precisely recognizes and destroys tumor cells while healthy surrounding tissue is minimally affected. 

Comparator treatment
Standard therapy with either CAPTEM (chemotherapy) or everolimus (immunosuppressive cancer therapy) or FOLFOX (chemotherapy), determined by the doctor based on individual benefit-risk assessment and according to institutional protocols, local prescribing information, local regulations or local guidelines.

Study objectives
Evaluate efficacy, safety and impact on quality of life.

Contact:

Peter MacCallum Cancer Centre

Melbourne VIC 3000, Australia 

Principle Investigator: A/Prof Michael Michael

Contact: (03) 8559 5000

Royal North Shore Hospital

St Leonards / Sydney NSW 2065, Australia

Principle Investigator: A/Prof Nick Pavlakis

Contact: (02) 9926 7111

Download Patient Flyer
Download Patient Brochure

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)

PARLuNET is a phase 1 dose-escalation study designed to evaluate the safety and tolerability of talazoparib (PARP Inhibitor) in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic and mid gut neuroendocrine tumour (NET).

Patients will receive 1 cycle of 177Lu-DOTA-Octreotate alone followed by 3 cycles of 177Lu-DOTA-Octreotate combined with 5 days of talazoparib.

This trial is looking to recruit 24 patients and if you would like to know if you are eligible, please ask your doctor to assess the inclusion criteria listed at PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours – Full Text View – ClinicalTrials.gov

Contact:

Grace Kong 03 8559 5000 or NMResearch@petermac.org

Research Manager: 03 8559 6602

Recruiting: NMResearch@petermac.org

Locations: Australia, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia

Sponsors and Collaborators

Peter MacCallum Cancer Centre, Australia

Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT)

Sponsor: Olivia Newton-John Cancer Research Institute
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Olivia Newton-John Cancer Research Institute
 

Brief Study Description:

The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups:

  1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded)
  2. Biliary tract cancers: Intrahepatic cholangiocarcinoma and gallbladder carcinoma
  3. Gynaecological malignancies: Ovarian clear cell carcinoma, uterine clear cell carcinoma, uterine/ovarian carcinosarcoma, uterine leiomyosarcoma and vaginal/vulva squamous cell carcinoma
  4. Mismatch repair protein deficient (MSI-H) cancers (excluding colorectal carcinoma).

The role of immunotherapy is being defined in more common cancer types, however because of their rarity, the efficacy of immunotherapy for these cancers is poorly defined.

This protocol provides an important opportunity to establish whether the combination of nivolumab & ipilimumab has efficacy in these cancers.

Contacts
Jodie Palmer, PhD (03)9496 3573  trials@onjcri.org.au
Sharon Reid (03) 9496 9143  trials@onjcri.org.au 
 
The study is available at sites around Australia. For more information and site locations  click here. 
 

Lutetium-177 OPS-201 for Progressive Metastatic Neuroendocrine Tumours

Official Title:      An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

The purpose of this clinical phase I/II study is to investigate the safety and tolerability of 177Lu-OPS201 used for the treatment of patients with neuroendocrine tumours (NETs). Secondary objectives of this study are the assessment of biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201.

Contact for trial:
Theranostics Australia +618 9091 1081 or email reception@theranostics.com.au

For more information on this trial, please click here

Table of Contents